Concomitant Inhibition of FASN and SREBP Provides a Promising Therapy for CTCL

SIMPLE SUMMARY: The biosynthesis of fatty acids catalysed by FASN plays an important oncogenic role in various malignancies but has not been reported in CTCL yet. Here, we show that FASN is highly expressed in both cell lines and primary cells from CTCL patients. The inhibition of FASN impairs cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Chi, Cheng, Harth, Lisa, Galera, Marina Ramírez, Torrealba, Marina Passos, Vadivel, Chella Krishna, Geisler, Carsten, Bonefeld, Charlotte Menné, Nielsen, Pia Rude, Bzorek, Michael, Becker, Jürgen C., Gjerdrum, Lise Mette Rahbek, Ødum, Niels, Woetmann, Anders
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496997/
https://www.ncbi.nlm.nih.gov/pubmed/36139650
http://dx.doi.org/10.3390/cancers14184491

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496997/
https://www.ncbi.nlm.nih.gov/pubmed/36139650
http://dx.doi.org/10.3390/cancers14184491

Ejemplares similares